Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | PIM1 | P11309 | 1/20 | 0.37 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.37 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | NR2C2 | P49116 | 1/20 | 0.37 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL509096 | 0.90 | HRH4 (0.48) | ALDH1A1KDM4EMAPTGAAHPGD | |
| SCHEMBL510233 | 0.89 | PIK3CA (0.47) | ALDH1A1MAPTSMN1; SMN2ROCK2HSD17B10 | |
| SCHEMBL508384 | 0.87 | ALDH1A1 (0.39) | ALDH1A1KDM4EMAPTGAAHPGD | |
| SCHEMBL509579 | 0.87 | EIF2AK4 (0.39) | ALDH1A1KDM4EMAPTGAAHPGD | |
| SCHEMBL509103 | 0.85 | WNT1 (0.37) | ALDH1A1MAPTPOLBSMN1; SMN2NPSR1 | |
| SCHEMBL13329922 | 0.81 | ALDH1A1 (0.43) | ALDH1A1KDM4EMAPTGAAHPGD | |
| SCHEMBL10170679 | 0.80 | CXCR4 (0.42) | ALDH1A1SMN1; SMN2CXCR4HSD17B10PIM1 | |
| SCHEMBL3406290 | 0.77 | KDM4E (0.43) | ALDH1A1KDM4EGAAHPGDPOLB | |
| SCHEMBL508635 | 0.77 | PIK3CA (0.48) | ALDH1A1KDM4EMAPTHPGDSMN1; SMN2 | |
| SCHEMBL509504 | 0.77 | ALDH1A1 (0.47) | ALDH1A1KDM4EMAPTGAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120028979-A1 | 2-(PIPERIDIN-1-YL)-4-HETEROCYCLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
| US-20120028979-A1 | 2-(PIPERIDIN-1-YL)-4-HETEROCYCLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2012-02-02 | — | — | US | disclosed |
| US-8071605-B2 | Piperidine compounds for use in the treatment of bacterial infections | ASTRAZENECA AB (SE) | 2011-12-06 | — | — | US | disclosed |
| US-8071605-B2 | Piperidine compounds for use in the treatment of bacterial infections | ASTRAZENECA AB (SE) | 2011-12-06 | — | — | US | disclosed |
| US-8071605-B2 | Piperidine compounds for use in the treatment of bacterial infections | ASTRAZENECA AB (SE) | 2011-12-06 | — | — | US | disclosed |
| EP-2376488-A1 | 2- (PIPERIDIN-1-YL) -4-HETEROCYCLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS | AstraZeneca AB (SE) | 2011-10-19 | — | — | EP | disclosed |
| US-20100173909-A1 | PIPERIDINE COMPOUNDS AND USES THEREOF - 596 | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | disclosed |
| US-20100173909-A1 | PIPERIDINE COMPOUNDS AND USES THEREOF - 596 | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | disclosed |
| US-20100173909-A1 | PIPERIDINE COMPOUNDS AND USES THEREOF - 596 | ASTRAZENECA AB (SE) | 2010-07-08 | — | — | US | disclosed |
| WO-2010067123-A1 | 2- (PIPERIDIN-1-YL) -4-HETEROCYCLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS | ASTRAZENECA AB (SE) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028979-A1 | 2-(PIPERIDIN-1-YL)-4-HETEROCYCLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS | TLR5, TLR2, PIR | ALDH1A1 119/4885KDM4E 3919/4885MAPT 2953/4885 |
| US-20100173909-A1 | PIPERIDINE COMPOUNDS AND USES THEREOF - 596 | NISCH, PAK6, MYD88 | ALDH1A1 609/4885KDM4E 2849/4885MAPT 2680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.